Showing 1 to 4 of 4 results
German Court Allows Unlicensed Drug Production for Rare Brain Tumor
A German court ruled that pharmacist Uwe-Bernd Rose can continue producing an unapproved drug containing ONC-201 for patients with a rare brain tumor, prioritizing their right to life and bodily integrity over strict regulatory adherence, despite legal challenges from an American company also develo...
German Court Allows Unlicensed Drug Production for Rare Brain Tumor
A German court ruled that pharmacist Uwe-Bernd Rose can continue producing an unapproved drug containing ONC-201 for patients with a rare brain tumor, prioritizing their right to life and bodily integrity over strict regulatory adherence, despite legal challenges from an American company also develo...
Progress
52% Bias Score
China Expands Medical Insurance, Cutting Drug Prices by 63%
China's National Healthcare Security Administration added 91 drugs to its medical insurance scheme in 2024, reducing patient costs by an estimated 7 billion USD and expanding coverage for various diseases, including tumors, diabetes, and rare diseases.
China Expands Medical Insurance, Cutting Drug Prices by 63%
China's National Healthcare Security Administration added 91 drugs to its medical insurance scheme in 2024, reducing patient costs by an estimated 7 billion USD and expanding coverage for various diseases, including tumors, diabetes, and rare diseases.
Progress
40% Bias Score
Long Waits at Athens EOPYY Pharmacies Expose Healthcare System Strain
Long queues at Athens' EOPYY pharmacies cause significant delays for patients needing high-cost medications, highlighting understaffing and insufficient geographical distribution of these facilities, impacting patients' health and well-being.
Long Waits at Athens EOPYY Pharmacies Expose Healthcare System Strain
Long queues at Athens' EOPYY pharmacies cause significant delays for patients needing high-cost medications, highlighting understaffing and insufficient geographical distribution of these facilities, impacting patients' health and well-being.
Progress
56% Bias Score
Lenacapavir: A Highly Effective but Expensive HIV Drug
Lenacapavir, a new HIV drug from Gilead, offers near-100% efficacy with twice-yearly injections but faces accessibility challenges due to its $40,000 annual cost, although Gilead is negotiating lower prices in 120 low-income countries.
Lenacapavir: A Highly Effective but Expensive HIV Drug
Lenacapavir, a new HIV drug from Gilead, offers near-100% efficacy with twice-yearly injections but faces accessibility challenges due to its $40,000 annual cost, although Gilead is negotiating lower prices in 120 low-income countries.
Progress
60% Bias Score
Showing 1 to 4 of 4 results